Chemotherapy Experts Refute ASCO Recommendations On Use Of Drug Sensitivity And Resistance Assays; Flawed Analytic Methods And Conflicts Of Interest Cited As Factors Behind ASCO Panel Findings

A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).

Back to news